Most cited papers from Certara (United States)

Certara (United States)

What are the most cited papers from Certara (United States)?

The most cited paper from Certara (United States) is "Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease" (Melanie Ann Felmlee, Robert S. Jones, Vivian Rodriguez‐Cruz et al., 2020), with 484 citations. Next come "Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial" (405) and "Evaluation of dosing strategy for pembrolizumab for oncology indications" (268).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 43 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease Melanie Ann Felmlee, Robert S. Jones, Vivian Rodriguez‐Cruz et al. · Pharmacological Reviews Open access	6 Mar 2020	484
2	Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial Gilmar Reis et al. · The Lancet Global Health Open access	28 Oct 2021	405
3	Evaluation of dosing strategy for pembrolizumab for oncology indications Tomoko Freshwater, Anna Georgieva Kondic, Malidi Ahamadi et al. · Journal for ImmunoTherapy of Cancer Open access	9 May 2017	268
4	Non-compartmental Analysis Johan Gabrielsson, DANIEL L. WEINER · Methods in molecular biology Book chapter	2012	266
5	Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load António Gonçalves, Julie Bertrand, Ruian Ke et al. · CPT Pharmacometrics & Systems Pharmacology Open access	18 Jun 2020	239
6	How COVID-19 has fundamentally changed clinical research in global health Jay Park, Robin Mogg, Gerald E. Smith et al. · The Lancet Global Health Open access	16 Apr 2021	227
7	Meta-Analysis of the Turnover of Intestinal Epithelia in Preclinical Animal Species and Humans Adam S. Darwich, Umair Aslam, Darren M. Ashcroft et al. · Drug Metabolism and Disposition Review	19 Sep 2014	209
8	Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy Adam S. Darwich, Thomas M. Polasek, Jeffrey K Aronson et al. · The Annual Review of Pharmacology and Toxicology ReviewOpen access	9 Oct 2020	197
9	Results From the IQ‐CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase Börje Darpö, Charles Benson, Corina Dota et al. · Clinical Pharmacology & Therapeutics	16 Mar 2015	181
10	Early Treatment with Pegylated Interferon Lambda for Covid-19 Gilmar Reis et al. · New England Journal of Medicine Open access	8 Feb 2023	179
11	Simultaneous Quantification of the Abundance of Several Cytochrome P450 and Uridine 5′-Diphospho-Glucuronosyltransferase Enzymes in Human Liver Microsomes Using Multiplexed Targeted Proteomics Brahim Achour, Matthew R. Russell, Jill Barber et al. · Drug Metabolism and Disposition	10 Jan 2014	167
12	Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort Essy Mozaffari, Aastha N. Chandak, Zhiji Zhang et al. · Clinical Infectious Diseases Open access	30 Sep 2021	123
13	A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers Patrick F. Smith, Janakan Krishnarajah, Philip A. Nunn et al. · British Journal of Clinical Pharmacology Open access	21 Jun 2017	105
14	Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa B. Alexander Yi, Debra Freedholm, Nancy Widener et al. · Journal of Thrombosis and Haemostasis Open access	29 Oct 2021	104
15	Pharmacokinetics and Pharmacodynamics of Intramuscular and Oral Betamethasone and Dexamethasone in Reproductive Age Women in India Alan Hall Jobe, Mark A. Milad, Thomas Peppard et al. · Clinical and Translational Science Open access	6 Dec 2019	102
16	The IQ‐CSRC Prospective Clinical Phase 1 Study: “Can Early QT Assessment Using Exposure Response Analysis Replace the Thorough QT Study?” Börje Darpö, Nenad Sarapa, Christine E. Garnett et al. · Annals of Noninvasive Electrocardiology Open access	30 Dec 2013	100
17	Artificial Intelligence and Machine Learning Applied at the Point of Care Zuzanna Angehrn, Liina Haldna, Anthe S. Zandvliet et al. · Frontiers in Pharmacology Open access	18 Jun 2020	93
18	A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy James R. Myette, Toshiki Kano, Hitoshi Suzuki et al. · Kidney International Open access	16 Mar 2019	92
19	Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study Ellie Hershberger, Susan E. Sloan, Kristin M. Narayan et al. · EBioMedicine Open access	9 Jan 2019	88
20	Nonlinear Mixed‐Effects Model Development and Simulation Using nlmixr and Related R Open‐Source Packages Matthew L. Fidler, Justin J. Wilkins, Richard Hooijmaijers et al. · CPT Pharmacometrics & Systems Pharmacology Open access	17 Jun 2019	85
21	Liquid Biopsy Enables Quantification of the Abundance and Interindividual Variability of Hepatic Enzymes and Transporters Brahim Achour, Zubida M. Al‐Majdoub, Agnieszka Grybos‐Gajniak et al. · Clinical Pharmacology & Therapeutics Open access	3 Nov 2020	84
22	Development of a Multicompartment Permeability‐Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs Lu Gaohua, J. R. Wedagedera, Ben G. Small et al. · CPT Pharmacometrics & Systems Pharmacology Open access	Oct 2015	84
23	Incidence of Adenovirus Infection in Hematopoietic Stem Cell Transplantation Recipients: Findings from the AdVance Study Petr Sedláček, Toni Petterson, Marie Robin et al. · Transplantation and Cellular Therapy Open access	19 Dec 2018	79
24	Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future Craig R. Rayner, Patrick F. Smith, David R. Andes et al. · Clinical Pharmacology & Therapeutics Open access	9 Feb 2021	78
25	In Vitro–In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells Matthew D. Harwood, Brahim Achour, Sibylle Neuhoff et al. · Drug Metabolism and Disposition	3 Dec 2015	75
26	Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: A Systematic Review Ranita Kirubakaran, SOPHIE LENA STOCKER, Stefanie Hennig et al. · Clinical Pharmacokinetics ReviewOpen access	11 Aug 2020	74
27	Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment David G. Kallend, Robert M. Stoekenbroek, Yanling He et al. · Journal of clinical lipidology Open access	10 Jan 2022	73
28	Physiologically Based Pharmacokinetic Modeling in Pregnancy: A Systematic Review of Published Models André Dallmann, Marc Pfister, John van den Anker et al. · Clinical Pharmacology & Therapeutics Review	10 Apr 2018	72
29	Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTcmodelling in a phase 1 study with oral rac-sotalol Börje Darpö, Dilip R. Karnad, Fabio Badilini et al. · British Journal of Clinical Pharmacology Open access	2 Jul 2013	71
30	A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants Fady I. Malik, Laura A Robertson, Danielle R. Armas et al. · JACC Basic to Translational Science Open access	Aug 2022	68
31	Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance John O. Miners, Thomas M. Polasek, Julie-Ann Hulin et al. · Pharmacology & Therapeutics	30 May 2023	67
32	Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors Ophelia Q. P. Yin, Yuan Xiong, Seiko Endo et al. · Clinical Pharmacology & Therapeutics Open access	29 Oct 2020	65
33	Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women Paola Mian, John N. van den Anker, Kristel Van Calsteren et al. · Clinical Pharmacokinetics Open access	25 Jul 2019	63
34	Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network L. Cucurull-Sanchez, Michael John Chappell, Vijayalakshmi Chelliah et al. · CPT Pharmacometrics & Systems Pharmacology Open access	23 Jan 2019	63
35	Dopamine D2 Occupancy as a Biomarker for Antipsychotics: Quantifying the Relationship with Efficacy and Extrapyramidal Symptoms Rik de Greef, Alan Maloney, Per Olsson et al. · The AAPS Journal Open access	23 Dec 2010	63
36	Cardiac Safety Research Consortium: Can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward Börje Darpö, Christine E. Garnett, Charles Benson et al. · American Heart Journal	6 Jun 2014	63
37	Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice Essy Mozaffari, Aastha N. Chandak, Robert Gottlieb et al. · Clinical Infectious Diseases Open access	8 Aug 2023	61
38	Virtual Twins: Understanding the Data Required for Model‐Informed Precision Dosing Thomas M. Polasek, Amin Rostami‐Hodjegan · Clinical Pharmacology & Therapeutics	14 Feb 2020	61
39	Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects Kelong Han, Mark Baker, Mark Lovern et al. · British Journal of Clinical Pharmacology Open access	13 Jun 2022	60
40	Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response Stephanus T. Malherbe et al. · EJNMMI Research Open access	10 Feb 2020	57
41	Immunogenicity of pembrolizumab in patients with advanced tumors Marianne J.H. van Vugt, Julie A. Stone, “Rik” H. J. M. M. De Greef et al. · Journal for ImmunoTherapy of Cancer Open access	8 Aug 2019	57
42	Characterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 Transporter Chie Emoto, Tsuyoshi Fukuda, TN Johnson et al. · CPT Pharmacometrics & Systems Pharmacology Open access	9 Dec 2016	57
43	Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan Ophelia Q. P. Yin, Hiroji Iwata, Chia‐Chi Lin et al. · Clinical Pharmacology & Therapeutics Open access	17 May 2021	56
44	Month 2 Culture Status and Treatment Duration as Predictors of Recurrence in Pulmonary Tuberculosis: Model Validation and Update Robert S. Wallis, Thomas Peppard, David J. Hermann · PLoS ONE Open access	29 Apr 2015	56
45	Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma Ken Ogasawara, Michael Dodds, Timothy R. Mack et al. · Clinical Pharmacokinetics Open access	14 Jun 2021	54
46	Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients Rachael A. Lawson, Christine E. Staatz, Christopher J. Fraser et al. · Clinical Pharmacokinetics	30 Oct 2020	54
47	Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168) Timothy D. Owens, Patrick F. Smith, Andrew David Redfern et al. · Clinical and Translational Science Open access	Nov 2021	53
48	Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage JE Edwards, Carl LaCerte, Thomas Peyret et al. · Clinical and Translational Science Open access	15 Oct 2016	51
49	Hallmarks of neurodegenerative disease: A systems pharmacology perspective Peter Bloomingdale, Tatiana Karelina, Vidya Ramakrishnan et al. · CPT Pharmacometrics & Systems Pharmacology Open access	27 Jul 2022	50
50	Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses Fredrika Hellgren, Alberto Cagigi, Rodrigo Arcoverde Cerveira et al. · Nature Communications Open access	22 Jun 2023	49

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.